Paclitaxel inhibits post-traumatic recurrent laryngeal nerve regeneration into the posterior cricoarytenoid muscle in a canine model - PubMed (original) (raw)
Comparative Study
. 2017 Mar;127(3):651-655.
doi: 10.1002/lary.26058. Epub 2016 Nov 30.
Affiliations
- PMID: 27900774
- DOI: 10.1002/lary.26058
Comparative Study
Paclitaxel inhibits post-traumatic recurrent laryngeal nerve regeneration into the posterior cricoarytenoid muscle in a canine model
Andrea M Park et al. Laryngoscope. 2017 Mar.
Abstract
Objectives/hypothesis: To investigate the efficacy of paclitaxel, a potent microtubule inhibitor with a more favorable therapeutic index as compared with vincristine, in preventing post-traumatic nerve regeneration of the recurrent laryngeal nerve into the posterior cricoarytenoid muscle in a canine laryngeal model.
Study design: Experimental animal study.
Methods: Forty-nine canine hemilaryngeal specimens were divided into five experimental groups. Under general anesthesia, a tracheostomy, recurrent laryngeal nerve (RLN) transection and repair, and laryngeal adductory pressures (LAP) were measured pre-RLN injury. The approach to the posterior cricoarytenoid (PCA) muscle for neurotoxin injection was transoral or open transcervical, at 0 or 3 months. At 6 months, postinjury LAPs were measured and the animals were sacrificed at 6 months to allow for laryngeal harvesting and analysis.
Results: Paclitaxel demonstrated increased mean laryngeal adductory pressures (70.6%) as compared with saline control (55.5%). The effect of paclitaxel was the same as observed with vincristine at 0 months and with a delayed injection at 3 months. There was no difference between transoral or open injection groups.
Conclusions: PCA muscle injection with paclitaxel resulted in improved strength of laryngeal adduction. This effect was similar to that of vincristine at both 0 and 3 months following nerve injury. A single intramuscular injection of paclitaxel was well tolerated. Additional human studies are needed to determine the degree of clinical benefit of this intervention.
Level of evidence: NA Laryngoscope, 127:651-655, 2017.
Keywords: Laryngeal disorder; paclitaxel; unilateral vocal fold paralysis; vincristine.
© 2016 The American Laryngological, Rhinological and Otological Society, Inc.
Publication types
MeSH terms
Substances
Grants and funding
- R01 DC010884/DC/NIDCD NIH HHS/United States
- P30 CA006973/CA/NCI NIH HHS/United States
- UL1 TR001079/TR/NCATS NIH HHS/United States
- S10 RR026824/RR/NCRR NIH HHS/United States
- UL1 TR001079/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials